Cord Blood News Volume 10.36 | Sep 13 2018

TOP STORY

Characterization and Targeting of Malignant Stem Cells in Patients with Advanced Myelodysplastic Syndromes

Scientists report that during evolution of myelodysplastic syndrome (MDS), malignant hematopoietic stem cells activate distinct cellular programs that render such cells susceptible to therapeutic intervention. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

The Effects of Apheresis, Storage Time, and Leukofiltration on Microparticle Formation in Apheresis Platelet Products

Higher‐level total microparticles (TMPs) and platelet (PLT) microparticles (PMPs), but lower‐level red blood cell-derived microparticles (RMPs), leukocyte‐derived microparticles (LMPs), and monocyte‐derived microparticles (MMPs) were detected in fresh platelets on the day of collection compared with those before collection. During storage, TMP, PMP, and RMP counts were significantly higher on day 3 and day 5, but MMP and LMP counts were only marginally higher on day 3 in PLT supernatants. [Transfusion] Abstract

Mesenchymal Stem Cell Interacted with PLCL Braided Scaffold Coated with Poly‐L‐Lysine/Hyaluronic Acid for Ligament Tissue Engineering

A technology to fabricate a multilayer braided scaffold with flexible and elastic poly (l‐lactide‐co‐caprolactone) has been recently pioneered. Polyelectrolyte multilayer films (PEM) with poly‐l‐lysine (PLL)/hyaluronic acid (HA) were deposited on this scaffold. After PEM modification, polygonal (PLL) and particle‐like (HA) structures were present on the braided scaffold with no significant variation of fibers Young’s modulus. Wharton’s jelly MSCs and bone marrow MSCs showed good metabolic activity on scaffolds. [J Biomed Mater Res A] Abstract

Wharton’s Jelly-Derived Mesenchymal Stem Cell Transplantation in a Patient with Hypoxic-Ischemic Encephalopathy

Wharton’s jelly (WJ)-derived MSCs have been introduced as a possible therapy in hypoxic-ischemic encephalopathy (HIE). Researchers report a 16-year-old boy who was treated with WJ-MSCs in the course of HIE due to post-cardiopulmonary resuscitation. After stem cell infusions, progressive improvements were shown in his neurological examination, neuroradiological, and neurophysiological findings. [Cell Transplant] Abstract

Evaluation of Dehydrated Human Umbilical Cord Biological Properties for Wound Care and Soft Tissue Healing

The authors characterized PURION^® PLUS Processed dehydrated human umbilical cord (dHUC) and evaluated the biological properties of this tissue that contribute to healing. This was performed through the characterization of the tissue composition, evaluation of in vitro cellular response to dHUC treatment, and in vivo bioresorption and tissue response in a rat model. [J Biomed Mater Res B Appl Biomater] Full Article

Platelet Engraftment after Allogenic Stem Cell Transplantation Is Monitored by Digital PCR without Interference by Platelet Support

In a feasibility study, consecutive daily peripheral blood samples from day 7 to day 20 post-transplantation were analyzed by digital PCR in 22 patients after allogeneic transplantation. Platelet engraftment according to PCR was defined as the third of at least three consecutive days of increasing levels exceeding 1,000/µL endogenous platelets. [Exp Hematol] Abstract

Umbilical Cord Mesenchymal Stem Cell Conditioned Medium Restored the Expression of Collagen II and Aggrecan in Nucleus Pulposus Mesenchymal Stem Cells Exposed to High Glucose

Investigators determined the effect of umbilical cord (UC) MSCs conditioned medium on high glucose (HG) induced degradation of nucleus pulposus MSCs produced extracellular matrix. Treatment with MSC-CM abolished the effect of HG on cell senescence. HG also significantly inhibited collagen II and aggrecan expression in nucleus pulposus MSCs. After MSC-CM treatment, the expression of these two extracellular matrix components was restored. [J Bone Miner Metab] Abstract

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

Mesenchymal Stem Cells as the Game‐Changing Tools in the Treatment of Various Organs Disorders: Mirage or Reality?

The authors introduce latest advances, methods, and applications of MSCs in gene therapy of various malignant organ disorders. Additionally, they cover the problems and challenges which researchers have faced with when trying to translate their basic experimental findings in MSCs research to clinically applicable therapeutics. [J Cell Physiol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Application for Sprycel (Dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Company announced that the FDA accepted its supplemental Biologics License Application for Sprycel in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. [Bristol-Myers Squibb Company] Press Release

Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for FLT3-Mutated AML

Daiichi Sankyo Company announced that quizartinib, an investigational FLT3 inhibitor, has been granted Orphan Drug designation by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of FLT3-mutated acute myeloid leukemia (AML). [Daiichi Sankyo Company] Press Release

SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

SELLAS Life Sciences Group, Inc. announced that the Committee for Orphan Medicinal Products of the European Medicines Agency has approved orphan medicinal product designation for galinpepimut-S, the company’s lead product candidate, for the treatment of multiple myeloma. [SELLAS Life Sciences Group, Inc.] Press Release

Oryzon Receives Approval to Start ALICE: A Phase IIa Clinical Trial in AML with Iadademstat (ORY-1001)

Oryzon Genomics has announced that it has received approval of a Clinical Trial Application, the European IND equivalent, from the Spanish Drug Agency to conduct a Phase IIa clinical study with iadademstat in elderly acute myeloid leukemia (AML) patients not eligible for intensive chemotherapy. [Oryzon Genomics] Press Release

Europe’s Academics Fail to Report Results for 90% of Clinical Trials

European academics are failing abysmally when it comes to reporting the results of clinical trials, a study has revealed. An analysis of data from the European Union’s Clinical Trial Register — published in The BMJ — shows that around 50% of the listed trials have not complied with guidelines that say results must be reported within 12 months. [Nature News] Editorial

Prominent Health Policy Researcher Resigns from Dartmouth Over Plagiarism Dispute

Dr. H. Gilbert Welch, one of the country’s top health care policy scholars, has resigned from his faculty position at Dartmouth College, after an investigation by the school concluded that he had committed research misconduct. [STAT News] Editorial

Peer Reviewers in Developing Nations Are Underrepresented, Report Suggests

Combined, scientists spend nearly 70 million hours peer reviewing manuscripts for scholarly journals every year, a new report says. But too much of the onus rests on researchers in wealthy countries, according to the report by the company Publons—based in London and Wellington—which enables researchers to track and claim credit for the peer reviews they perform. [ScienceInsider] Editorial

NEW Transplantation and Cellular Therapy Meetings (TCT) of ASBMT and CIBMTR
February 20-24, 2019
Houston, Texas, United States

Visit our events page to see a complete list of events in the community.

NEW Research Associate – Leukemia and Lymphoma (University College London)

Postdoctoral Fellow – Epigenetics of Hematopoietic Stem Cell Development and Disorders (Nationwide Children’s Hospital)

Bioinformatician – Single Cell Biology and Reprogramming (Lund University Stem Cell Center)

Adjunct Principal Investigator Positions – Molecular Medicine (CeMM and LBI-RUD)

Postdoctoral Researcher – Interdisciplinary (Oregon Health & Science University)

Institute Sr Research Scientist – Flow Cytometry (MD Anderson Cancer Center)

Post-Doctoral Fellow or Research Scientist – Transplant Immunology (Medical College of Wisconsin)

Postdoctorial Research Fellow – Transplantation and Tumor Immunology (Medical University of South Carolina)

Faculty Investigator – Cancer (University of Alabama at Birmingham)

Postdoctoral Associate – Gene Regulation and/or Cancer Biology (The University of North Carolina at Chapel Hill)

Scientific Research Positions – Various Subjects (Shanghai General Hospital)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.